Sovereign AI

Pharma Data Laws: US, EU and UK

Summary of Pharma and biotech data rules by jurisdiction
JurisdictionNumber of rulesMain rulesLast reviewed
European Union4European Health Data Space Regulation, Regulation (EU) 2025/327 (2025); Clinical Trials Regulation, Regulation (EU) No 536/2014; Good Manufacturing Practice Directive, Commission Directive (EU) 2017/1572 (2017); and 1 more13 November 2026
United Kingdom4Health Service (Control of Patient Information) Regulations 2002 (SI 2002/1438) (2002); Human Tissue Act 2004; Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031) (2004); and 1 more13 November 2026
United States6Federal Policy for the Protection of Human Subjects (Common Rule), 45 CFR Part 46; FDA electronic records and electronic signatures, 21 CFR Part 11; Current good manufacturing practice for finished pharmaceuticals, 21 CFR Part 211; and 3 more13 November 2026

European Union

Data protection

European Health Data Space Regulation, Regulation (EU) 2025/327 (2025)

Enacted, not yet in force. Takes effect on 26 March 2027.

Sets rules for access to and exchange of electronic health data, and for its secondary use. It entered into force in 2025 and applies from 26 March 2027. Primary use duties are staged to 2029 and 2031. The chapter on secondary use applies from 26 March 2029.

Applies to: Health care providers, electronic health record system makers and users of health data, including pharma and biotech companies.

Source: Regulation (EU) 2025/327, updated on 13 November 2026.

Also covered in: Hospital data laws.

Sector rules

Clinical Trials Regulation, Regulation (EU) No 536/2014

The clinical trial master file must be archived for at least 25 years (Article 58).

Applies to: Sponsors and investigators of clinical trials in the EU.

Source: Regulation (EU) No 536/2014, updated on 13 November 2026.

Good Manufacturing Practice Directive, Commission Directive (EU) 2017/1572 (2017)

Manufacturers must validate electronic data processing systems before use (Article 9(2)). The duty applies through national law.

Applies to: Manufacturers of medicinal products for human use.

Source: Commission Directive (EU) 2017/1572, updated on 13 November 2026.

Pharmacovigilance Implementing Regulation, Regulation (EU) No 520/2012

Marketing authorization holders must keep a pharmacovigilance system master file (Articles 2 to 6) and manage and retain records (Article 12).

Applies to: Holders of marketing authorizations for medicines.

Source: Commission Implementing Regulation (EU) No 520/2012, updated on 13 November 2026.

Sources

  1. Regulation (EU) 2025/327, updated on 13 November 2026.
  2. Regulation (EU) No 536/2014, updated on 13 November 2026.
  3. Commission Directive (EU) 2017/1572, updated on 13 November 2026.
  4. Commission Implementing Regulation (EU) No 520/2012, updated on 13 November 2026.

United Kingdom

Data protection

Health Service (Control of Patient Information) Regulations 2002 (SI 2002/1438) (2002)

Confidential patient information may be processed for medical purposes, including research, with approval from the Health Research Authority or the Secretary of State (regulation 5).

Applies to: Hospitals, researchers, pharma companies and others that process confidential patient information.

Source: SI 2002/1438, updated on 13 November 2026.

Also covered in: Hospital data laws.

Human Tissue Act 2004

It is an offense to analyze DNA without qualifying consent, unless an exception applies (section 45).

Applies to: Pharma and biotech companies, research labs, universities and others that hold human tissue.

Source: Human Tissue Act 2004, section 45, updated on 13 November 2026.

Also covered in: University and research data laws.

Sector rules

Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031) (2004)

The sponsor must keep a trial master file (regulation 31A). Further changes made by SI 2025/1249 are not yet all in force.

Applies to: Sponsors and investigators of clinical trials in the UK.

Source: SI 2004/1031, regulation 31A, updated on 13 November 2026.

Human Medicines Regulations 2012 (SI 2012/1916) (2012)

Marketing authorization holders must operate a pharmacovigilance system (regulation 182). Manufacturers must meet good manufacturing practice (regulation 41).

Applies to: Holders of marketing authorizations and manufacturers of medicines in the UK.

Source: SI 2012/1916, regulation 182, updated on 13 November 2026.

Sources

  1. SI 2002/1438, updated on 13 November 2026.
  2. Human Tissue Act 2004, section 45, updated on 13 November 2026.
  3. SI 2004/1031, regulation 31A, updated on 13 November 2026.
  4. SI 2012/1916, regulation 182, updated on 13 November 2026.

United States

Data protection

Federal Policy for the Protection of Human Subjects (Common Rule), 45 CFR Part 46

Sets protections for human subjects in research that federal agencies conduct or support. The 2018 revision is current.

Applies to: Research that a federal department or agency conducts or supports, including research by companies, labs and universities.

Source: 45 CFR Part 46, updated on 13 November 2026.

Also covered in: University and research data laws.

Sector rules

FDA electronic records and electronic signatures, 21 CFR Part 11

Sets rules for electronic records and electronic signatures that FDA rules require. Section 11.10(e) requires audit trails.

Applies to: Drug and biotech companies and others that keep FDA-required records electronically.

Source: 21 CFR Part 11, updated on 13 November 2026.

Current good manufacturing practice for finished pharmaceuticals, 21 CFR Part 211

Sets controls for computer systems used in drug manufacturing (section 211.68). Records must be kept for at least 1 year after the batch expiry date (section 211.180).

Applies to: Manufacturers of finished drug products.

Source: 21 CFR 211.68 and 211.180, updated on 13 November 2026.

Good Laboratory Practice for nonclinical laboratory studies, 21 CFR Part 58

Raw data, documentation and final reports of nonclinical studies must be kept in archives (section 58.190).

Applies to: Testing facilities that run nonclinical studies for FDA submissions.

Source: 21 CFR 58.190, updated on 13 November 2026.

FDA clinical investigation rules, 21 CFR Parts 50, 56 and 312

Set rules for FDA-regulated clinical investigations. Investigators must keep study records for 2 years after approval or after the investigation is discontinued (section 312.62(c)).

Applies to: Sponsors, investigators and institutions that run FDA-regulated clinical investigations, including pharma companies, research labs and universities.

Source: 21 CFR 312.62, updated on 13 November 2026.

Also covered in: University and research data laws.

Drug Supply Chain Security Act, 21 U.S.C. 360eee-1 (2013)

Trading partners must use secure, interoperable, electronic tracing of products at the package level. This requirement has applied since 27 November 2023.

Applies to: Manufacturers, repackagers, wholesale distributors and dispensers of prescription drugs.

Source: 21 U.S.C. 360eee-1, updated on 13 November 2026.

Sources

  1. 45 CFR Part 46, updated on 13 November 2026.
  2. 21 CFR Part 11, updated on 13 November 2026.
  3. 21 CFR 211.68 and 211.180, updated on 13 November 2026.
  4. 21 CFR 58.190, updated on 13 November 2026.
  5. 21 CFR 312.62, updated on 13 November 2026.
  6. 21 U.S.C. 360eee-1, updated on 13 November 2026.

This guide is general information and not legal advice. Confirm requirements with qualified counsel.

Guide version 1.0 · Last reviewed November 2026

Frequently asked questions

Do pharma and biotech companies need sovereign AI?

None of the pharma and biotech rules in this guide requires sovereign AI. Sovereign AI here refers to AI whose data, models and computing remain under the legal control of a chosen country or organization, such as a system hosted in-country with no access by foreign authorities. Under 21 CFR 11.10, persons who use closed systems for electronic records "shall employ procedures and controls designed to ensure the authenticity, integrity, and, when appropriate, the confidentiality of electronic records". For secondary use of EU health data, "Health data access bodies shall provide access to electronic health data pursuant to a data permit only through a secure processing environment" (European Health Data Space Regulation, Article 73(1)).

How long must clinical trial records be kept?

In the EU, the clinical trial master file must be archived for at least 25 years. In the US, investigators keep records for 2 years after approval or after the investigation is discontinued. In the UK, the sponsor must keep a trial master file.

What do FDA rules require for electronic records?

21 CFR Part 11 requires audit trails for electronic records that FDA rules require. 21 CFR 211.68 sets controls for computer systems used in drug manufacturing.

When does the European Health Data Space apply?

The regulation applies from 26 March 2027. Its rules on secondary use of health data apply from 26 March 2029.

Plan a sovereign AI deployment

Talk with the team about planning AI infrastructure for pharma and biotech companies.